Atlanta Black Star on MSN
‘Is Dr. Oz Stupid?!’: Dr. Oz Tries to Explain Trump’s MAGA Math — But His Bizarre Excuse Leaves the Host Stunned and Viewers Convinced He’s Terrified
Dr. Oz's math meltdown defending Trump's outlandish claims will leave you stunned and questioning everything! #DrOz #TrumpMath #ViralVideo ...
12hon MSNOpinion
MIKE DAVIS: Foreign weight-loss drugmaker seeks fat profits by gobbling up American upstart
Novo Nordisk attempts to acquire weight-loss drug company Metsera during government shutdown, potentially avoiding FTC ...
The middle-aged cocaine epidemic in Australia is only getting worse. If we keep going down this path, older users will pay ...
Prescription drugs often cost more in the U.S. than anywhere else, and most patients have no idea what they'll actually pay ...
TheHealthSite on MSN
Ozempic, Mounjaro, And Wegovy: Weight-Loss Revolution Spreading From US, UK, To India, But At What Cost?
The FDA-approved medications for weight loss and diabetes remain a life-changing therapy in many countries, and for some individuals, it is an affordable luxury. Let's delve deep into how prices vary ...
In late October 2025, Point32Health, Massachusetts’ second-largest health insurer, announced its second major round of ...
Coming up: earnings from AMD, Palantir, top pharmaceutical and tech firms; private-sector employment report; consumer sentiment.
Three pharma companies that have delivered the highest average 5-year ROCE are all into manufacturing the same type of ...
AlterNet on MSN
Midwestern Trump country is suffering from MAGA economy
In 2024, Donald Trump became the first president in U.S. history to win an election despite four criminal indictments — one ...
AstraZeneca has seen its fair value per share revised upward from $140.96 to $144.38. This change reflects growing analyst confidence in the company’s innovative drug pipeline. The increase is driven ...
They found that developers using the AI tool experienced productivity gains of more than 26 per cent — lower than the figure ...
The NCLAT ruled that the CCI cannot investigate disputes concerning patented products, asserting the Patent Act's precedence over the Competition Act.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results